Skip to main content
Clinical Trials/ACTRN12609000850279
ACTRN12609000850279
Not yet recruiting
Phase 3

In adults with Chronic Obstructive Pulmonary Disease (COPD), is corticosteroid combined with long-acting beta-agonist effective in forced expiratory volume in one second (FEV1) values, as compared to corticosteroid?

Aché Laboratories0 sites136 target enrollmentOctober 1, 2009

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COPD (Chronic obstructive pulmonary disease)
Sponsor
Aché Laboratories
Enrollment
136
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Aché Laboratories

Eligibility Criteria

Inclusion Criteria

  • moderate or severe COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease)
  • smoker or former smoker

Exclusion Criteria

  • Hospitalization due to COPD up to 4 weeks before screening visit
  • Subjects who have required treatment with oral corticosteroids, anti\-leukotriene, immunoglobulins, beta\-blockers, digitalis, itraconazole 2 months prior to Visit 1

Outcomes

Primary Outcomes

Not specified

Similar Trials